Calgary, Alberta – TheNewswire - October 26, 2021 - Ocumetics Technology Corp. (TSXV:OTC) (“Ocumetics”) is pleased to announce that it has commenced the first phase of a clinical trial program for its initial product, the Bionic Lens.

“We’ve been busy since our successful financing and reverse takeover of a public shell in August,” says Dr. Mark Lee, President and CEO of Ocumetics.

“After 14 years of research and development, our founder, Dr. Garth Webb, recently finalized the design of the two primary components of the Bionic Lens, the lens retainer and the lens itself,” adds Dr. Lee. “We subsequently engaged with a partner to design the tooling to be used to fabricate the Bionic Lens components. With the tooling design completed, our partner has fabricated sufficient prototype retainers to commence our pilot studies.”

‘We are delighted to have now entered this first phase of the clinical trials process for the retainer component of the Bionic Lens,” adds Dr. Lee. “Ocumetics will be providing regular updates, as we complete each successive phase of the clinical trials.”

Dr. Garth Webb, Founder, Chief Scientific Officer and Chairman of the Board of Ocumetics, developed the Bionic Lens to address many of the shortcomings of lens replacement options he observed in his professional practice with patients undergoing cataract and other procedures. While existing lens replacement products have improved over the years, the limitations of current technologies were self-evident to Dr. Webb. The Bionic Lens was designed to eliminate the need for corrective lenses for people of all ages without many of the liabilities associated with other alternatives.

About Ocumetics

Ocumetics Technology Corp. (TSXV:“OTC”) is a Canadian research and product development company that specializes in adaptive lens designs. Ocumetics is in the clinical trial stage of a game-changing technology for the ophthalmic industry - the Bionic Lens. The Bionic Lens is an expandable intraocular lens that fits within the natural lens compartment of the eye to completely eliminate the need for corrective lenses. It re-establishes the natural kinetics of the eye muscles to facilitate the eye’s ability to shift focus effortlessly from distance to near and very near range.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Dr. Mark Lee

President and CEO

(604) 832-6052

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain “forward-looking statements” under applicable Canadian securities legislation.  Forward-looking statements include, but are not limited to, statements with respect to the commencement, timing and scope of the clinical trial program outlined above and that it will be conducted as expected.  Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include but are not limited to: operational matters, historical trends, current conditions and expected future developments, access to financing as well as other considerations that are believed to be appropriate in the circumstances.  There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.  The Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.